Developer docs
API playgroundTry for free, no card

Search company profiles

Lyocontract

Full company profile

uuid000hlbu

Namestring
Lyocontract
Legal namestring
LYOCONTRACT GmbH
Websiteurl
lyocontract.de
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Lyocontract GmbH is a Germany-based contract development and manufacturing organization (CDMO) specializing in GMP-compliant aseptic filling and lyophilization (freeze-drying) of parenteral drugs in vials for human and veterinary use. Founded in 2007 as Fermentation-Biotec GmbH and operational since 2012, the company operates from a single manufacturing site in Ilsenburg, Saxony-Anhalt, equipped with a fully automated Bosch aseptic filling line, custom HOF Sonderanlagenbau freeze-dryers (58 sqm shelf area, 800 kg total ice capacity, CIP/SIP-enabled, including organic solvent processing), a non-GMP development freeze-dryer for cycle scale-up, and an in-house analytical laboratory (HPLC, IR, TOC, UV-VIS, Karl Fischer). It also offers high-speed labeling and packaging (up to 30,000 vials/hour for 2R format) with EU Falsified Medicines Directive serialization capability.

The company's core services are organized around four integrated offerings: aseptic filling, lyophilization, analytical testing, and packaging. It serves pharmaceutical companies globally on a fee-for-service basis, with pricing negotiated per project and not publicly disclosed. Customer acquisition runs through direct B2B sales, industry conferences, and the professional website (available in German and English). The company is FDA compliant and has held GMP certification since 2012.

Lyocontract was majority-owned by Lyomark Pharma GmbH from August 2017 until June 2024, when it was acquired by US-based private equity firm Great Point Partners, who positioned the deal as expanding a healthcare platform into aseptic liquid filling, lyophilization, and injectable drug packaging. The company employs 11–50 people and is led by Managing Director Dr. Tino Galgon.

Short descriptiontext

Lyocontract GmbH is a German CDMO providing GMP-compliant aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for global pharmaceutical clients, operating from a single Ilsenburg site and acquired by Great Point Partners in 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIlsenburg, Germany
HQ citystring
Ilsenburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, aseptic vial filling, lyophilization services, parenteral drug manufacturing, GMP contract manufacturing
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Lyocontract operates as a contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services on a fee-for-service basis. Services include aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for pharmaceutical clients. Revenue is generated through manufacturing contracts with pharmaceutical companies.

lyocontract.de
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Lyocontract is a contract development and manufacturing organization (CDMO) that performs GMP-compliant aseptic filling and freeze-drying (lyophilization) of parenteral drugs in vials, complemented by in-house analytical testing and high-speed packaging with serialization. The company serves pharmaceutical clients in Germany and worldwide as a fee-for-service manufacturer of sterile liquid and freeze-dried injectable products for human and veterinary use.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lyocontract GmbH is a contract manufacturing organization (CMO) offering a comprehensive range of services centered on aseptic filling and freeze-drying of parenteral drugs in vials. The company provides four integrated core services: Aseptic Filling (GMP-compliant sterile vial filling using automated Bosch production line), Lyophilization (freeze-drying using custom HOF freeze-dryers with development capabilities), Analytical Testing (in-house laboratory with HPLC, IR, TOC, Karl Fischer analysis), and Packaging (labeling and serialization). Founded in 2007 and operational since 2012, the company was acquired by Great Point Partners in June 2024, expanding its capabilities in aseptic liquid filling and injectable drug packaging.

Product and service4 records
1Aseptic Filling
CategoryContract Manufacturing Service
Description

GMP-compliant sterile filling of parenteral drugs into vials using a fully automated Bosch production line, for human and veterinary medicinal drugs. The service is targeted at pharmaceutical companies that need to outsource aseptic filling under FDA-compliant and GMP-certified conditions.

2Lyophilization (Freeze-Drying)
CategoryContract Manufacturing Service
Description

Freeze-drying of parenteral drugs in vials using custom-made HOF Sonderanlagenbau GMP freeze-dryers (58 sqm shelf area, 800 kg total ice capacity) with CIP/SIP capability, including lyophilization of pharmaceuticals with organic solvents. Includes development and optimization of freeze-drying programs via a non-GMP development freeze-dryer. Targeted at pharmaceutical companies requiring commercial or development-scale lyophilization capacity.

3Analytical Testing
CategoryAnalytical / Quality Control Service
Description

In-house analytical services using 4 HPLC units, IR spectrophotometer, TOC analyzer, UV-VIS spectrometer, and Karl Fischer titrator for quality control of raw materials, in-process controls, and final product analysis, as well as process and method transfers and process and method validation. Targeted at pharmaceutical companies needing integrated QC and regulatory support for parenteral drug manufacturing.

4Packaging and Serialization
CategoryContract Packaging Service
Description

Full-service packaging and labeling using a Brausch + Ströbel labeling machine (capacity 13,800 vials/hour for 100H format or 30,000 vials/hour for 2R format) and a KBA Metronic box printer, including variable data printing (batch number, expiration date) and serialization of folding boxes per EU Directive 2011/62/EU (Falsified Medicines Directive). Targeted at pharmaceutical companies needing compliant, high-speed packaging and anti-counterfeiting serialization for parenteral drug products.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-08-01
Description

In August 2017, Lyomark Pharma GmbH became the majority shareholder of LYOCONTRACT GmbH. Both companies are privately held and continue to be managed independently. This partnership provides strategic alignment within the pharmaceutical manufacturing sector.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyocontract

Pharmaceutical Contract Manufacturing (CDMO)lyocontract.de

Lyocontract GmbH is a German CDMO providing GMP-compliant aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for global pharmaceutical clients, operating from a single Ilsenburg site and acquired by Great Point Partners in 2024.

What Lyocontract does

Lyocontract GmbH is a Germany-based contract development and manufacturing organization (CDMO) specializing in GMP-compliant aseptic filling and lyophilization (freeze-drying) of parenteral drugs in vials for human and veterinary use. Founded in 2007 as Fermentation-Biotec GmbH and operational since 2012, the company operates from a single manufacturing site in Ilsenburg, Saxony-Anhalt, equipped with a fully automated Bosch aseptic filling line, custom HOF Sonderanlagenbau freeze-dryers (58 sqm shelf area, 800 kg total ice capacity, CIP/SIP-enabled, including organic solvent processing), a non-GMP development freeze-dryer for cycle scale-up, and an in-house analytical laboratory (HPLC, IR, TOC, UV-VIS, Karl Fischer). It also offers high-speed labeling and packaging (up to 30,000 vials/hour for 2R format) with EU Falsified Medicines Directive serialization capability.

The company's core services are organized around four integrated offerings: aseptic filling, lyophilization, analytical testing, and packaging. It serves pharmaceutical companies globally on a fee-for-service basis, with pricing negotiated per project and not publicly disclosed. Customer acquisition runs through direct B2B sales, industry conferences, and the professional website (available in German and English). The company is FDA compliant and has held GMP certification since 2012.

Lyocontract was majority-owned by Lyomark Pharma GmbH from August 2017 until June 2024, when it was acquired by US-based private equity firm Great Point Partners, who positioned the deal as expanding a healthcare platform into aseptic liquid filling, lyophilization, and injectable drug packaging. The company employs 11–50 people and is led by Managing Director Dr. Tino Galgon.

Lyocontract firmographics

Firmographics
Name
Lyocontract
Legal name
LYOCONTRACT GmbH
Website
https://lyocontract.de
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Lyocontract GmbH is a German CDMO providing GMP-compliant aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for global pharmaceutical clients, operating from a single Ilsenburg site and acquired by Great Point Partners in 2024.
Ownership category
akta.pro rank

Where Lyocontract is headquartered

Location

Headquarters

HQ city
Ilsenburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Lyocontract business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Lyocontract operates as a contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services on a fee-for-service basis. Services include aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for pharmaceutical clients. Revenue is generated through manufacturing contracts with pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Lyocontract product offering

Product offering

Core offering

Lyocontract is a contract development and manufacturing organization (CDMO) that performs GMP-compliant aseptic filling and freeze-drying (lyophilization) of parenteral drugs in vials, complemented by in-house analytical testing and high-speed packaging with serialization. The company serves pharmaceutical clients in Germany and worldwide as a fee-for-service manufacturer of sterile liquid and freeze-dried injectable products for human and veterinary use.

Product overview

Lyocontract GmbH is a contract manufacturing organization (CMO) offering a comprehensive range of services centered on aseptic filling and freeze-drying of parenteral drugs in vials. The company provides four integrated core services: Aseptic Filling (GMP-compliant sterile vial filling using automated Bosch production line), Lyophilization (freeze-drying using custom HOF freeze-dryers with development capabilities), Analytical Testing (in-house laboratory with HPLC, IR, TOC, Karl Fischer analysis), and Packaging (labeling and serialization). Founded in 2007 and operational since 2012, the company was acquired by Great Point Partners in June 2024, expanding its capabilities in aseptic liquid filling and injectable drug packaging.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aseptic Filling GMP-compliant sterile filling of parenteral drugs into vials using a fully automated Bosch production line, for human and veterinary medicinal drugs. The service is targeted at pharmaceutical companies that need to outsource aseptic filling under FDA-compliant and GMP-certified conditions.
  • Lyophilization (Freeze-Drying) Freeze-drying of parenteral drugs in vials using custom-made HOF Sonderanlagenbau GMP freeze-dryers (58 sqm shelf area, 800 kg total ice capacity) with CIP/SIP capability, including lyophilization of pharmaceuticals with organic solvents. Includes development and optimization of freeze-drying programs via a non-GMP development freeze-dryer. Targeted at pharmaceutical companies requiring commercial or development-scale lyophilization capacity.
  • Analytical Testing In-house analytical services using 4 HPLC units, IR spectrophotometer, TOC analyzer, UV-VIS spectrometer, and Karl Fischer titrator for quality control of raw materials, in-process controls, and final product analysis, as well as process and method transfers and process and method validation. Targeted at pharmaceutical companies needing integrated QC and regulatory support for parenteral drug manufacturing.
  • Packaging and Serialization Full-service packaging and labeling using a Brausch + Ströbel labeling machine (capacity 13,800 vials/hour for 100H format or 30,000 vials/hour for 2R format) and a KBA Metronic box printer, including variable data printing (batch number, expiration date) and serialization of folding boxes per EU Directive 2011/62/EU (Falsified Medicines Directive). Targeted at pharmaceutical companies needing compliant, high-speed packaging and anti-counterfeiting serialization for parenteral drug products.

Companies that use Lyocontract

Customer profile

Segments1 record

Ideal customer profiles2 records

Lyocontract technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Lyocontract partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lyomark Pharma GmbHmajorStrategic or Co-development Partner · 1 August 2017In August 2017, Lyomark Pharma GmbH became the majority shareholder of LYOCONTRACT GmbH. Both companies are privately held and continue to be managed independently. This partnership provides strategic alignment within the pharmaceutical manufacturing sector.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Lyocontract competitors and assessment

Company assessment

Market position

Strengths1 record

Weaknesses4 records

Competitive moat3 records

Customer concentration

Lyocontract social profiles

Digital presence

Lyocontract compliance and trust

Trust signal

Compliance2 records

Lyocontract financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyocontract leadership team

Management profile

Number of profiles

Profiles1 record

Lyocontract funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyocontract M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyocontract

What does Lyocontract do?

Lyocontract is a contract development and manufacturing organization (CDMO) that performs GMP-compliant aseptic filling and freeze-drying (lyophilization) of parenteral drugs in vials, complemented by in-house analytical testing and high-speed packaging with serialization. The company serves pharmaceutical clients in Germany and worldwide as a fee-for-service manufacturer of sterile liquid and freeze-dried injectable products for human and veterinary use.

Is Lyocontract a public or private company?

Lyocontract is a private company. It is classified as private equity controlled and is currently operating.

When was Lyocontract founded?

Lyocontract was founded in 2007. It employs 11 to 50 people.

Where is Lyocontract based?

Lyocontract is headquartered in Ilsenburg, Germany, in the Europe region.

How does Lyocontract make money?

One revenue line is on record: contract Manufacturing Services.

Does Lyocontract have an API?

No public API is recorded for Lyocontract.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com released its 2026 Biopharmaceutical CMO and CRO Market Report, showing the market growing from $35.6 billion in 2025 to $38.01 billion in 2026 at a 6.8% CAGR, with projections reaching $48.79 billion by 2030 at a 6.4% CAGR. The growth is driven by increasing biologic drug development complexity, rising R&D costs, expanded clinical trial activities, and the surge in biosimilar development. Notable strategic transactions in the sector include Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH, both in June 2024, while North America remains the largest regional market and Asia-Pacific is forecast to be the fastest-growing region.YahooBiopharmaceutical CMO and CRO Research Report 2026: $48.79 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe biopharmaceutical Contract Manufacturing Organizations (CMO) and Contract Research Organizations (CRO) market is projected to grow from $38.01 billion in 2026 to $48.79 billion by 2030, driven by increasing R&D investments, demand for biologics, and rising clinical trial activities. Strategic partnerships and acquisitions are reshaping the competitive landscape, including Abzena plc. 's collaboration with Argonaut Manufacturing Services Inc. and Great Point Partners' acquisition of Lyocontract GmbH. Industry trends indicate continued outsourcing of biologic drug manufacturing and expansion of cell and gene therapy capabilities as key growth drivers through 2030.openPR.comTop Players and Competitive Overview in the Biopharmaceutical CMO and CRO MarketThe biopharmaceutical contract manufacturing organization (CMO) and contract research organization (CRO) market is projected to reach $48.79 billion by 2030, growing at a compound annual growth rate of 6.4%, driven by rising demand for biologics manufacturing, cell and gene therapy investment, and digitalized CRO services. In June 2024, Great Point Partners, a US-based investment firm, acquired Lyocontract GmbH, a Germany-based contract development and manufacturing organization, expanding its capabilities to include aseptic liquid filling, freeze-drying, and injectable drug packaging. Separately, Hologic Inc. received FDA clearance in February 2024 for its AI-powered Genius Digital Diagnostics System for cervical cancer screening.Business Wire BlogGreat Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMOGreat Point Partners acquired Lyocontract GmbH, a German drug product CDMO, with Rantum Capital providing debt financing. The acquisition marks GPP's first investment sourced and executed by its European team. GPP aims to help Lyocontract scale and expand its global capabilities.BioSpaceGreat Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMOGreat Point Partners, an investment firm based in Greenwich, Connecticut, has acquired Lyocontract GmbH, a drug product contract development and manufacturing organization located in Ilsenburg, Germany. This acquisition expands Lyocontract's global footprint and enhances its service offerings in response to growing demand for lyophilization services. The deal marks the first investment executed by GPP’s European team from its London office and signifies GPP's strategy to help health care companies grow internationally.ContractpharmaGreat Point Partners Acquires Lyocontract GmbHGreat Point Partners, a healthcare-focused investment firm, has acquired Lyocontract GmbH, a German contract development and manufacturing organization specializing in lyophilization services. The acquisition aims to leverage GPP's capital and strategic counsel to help Lyocontract scale its global capabilities amid growing demand for these pharmaceutical services.ThemiddlemarketGreat Point Partners Acquires LyocontractGreat Point Partners has acquired Lyocontract, an independent drug product contract development and manufacturing organization based in Germany. This acquisition is part of Great Point Partners' strategy to expand its influence in the healthcare sector. The deal reflects ongoing interest in contract manufacturing within the pharmaceutical industry.